Introduction
Chronic obstructive pulmonary disease (COPD) represents a significant cause of global morbidity and mortality, with a substantial economic impact. Recent changes in the Global initiative for chronic Obstructive Lung Disease (GOLD) guidance refined the classification of patients for treatment using a combination of Spirometry, assessment of symptoms, and/or frequency of exacerbations. The aim of treatment remains to reduce existing symptoms while decreasing the risk of future adverse health events 1 .
Method
QVA149, a dual bronchodilator combining Indacaterol (110 µg) and Glycopyrronium (50 µg), was chosen to evaluate on direct patient-reported dyspnoea in patients with moderate-to severe COPD. In this multicentre, blinded, double-dummy, three-period crossover study, 247 patients were randomized to once-daily QVA149 110/50 µg, placebo or tiotropium 18 µg. Superiority of QVA149 versus placebo (primary objective) and tiotropium (secondary objective) was assessed for improvement in dyspnoea via the Self Administered Computerized (SAC) version of the Baseline and Transition Dyspnoea Index (BDI/TDI) after 6 weeks 4 .
Secondary endpoints included lung function, rescue medication use and safety. After 6 weeks, the SAC TDI total score was significantly higher with QVA149 versus and tiotropium. QVA149 provided significant improvements in lung function and lower use of rescue medications versus placebo and tiotropium. All treatments were well tolerated.
Discussion
Long-acting bronchodilators are the mainstay of therapy due to their proven efficacy. Combinations of longacting ß2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are an alternative treatment recommendation for patients in GOLD Groups B to D and those who remain symptomatic when treated with a single bronchodilator 2 .
Original QVA149 provided statistically significant and clinically meaningful bronchodilation that was sustained throughout the treatment periods versus all comparators in all studies. In addition, QVA149 reduced the rate of all exacerbations by 31% and significantly delayed the time to first exacerbation versus SFC in the ILLUMINATE trial 4 .
Conclusion
As data supporting the efficacy and safety of LABA/LAMA fixed-dose combinations continue to emerge, this once daily dual bronchodilation may feature increasingly in future COPD treatment algorithms 3 . Although like other modern treatment options in COPD, this new treatment will emerge as an expensive one as well. More randomized control trials are ongoing to see the effect on mortality in future, but we may conclude that once daily dual bronchodilation with LABA/LAMA has significant reduction in morbidity especially in moderate to severe cases of COPD.
